22nd Century Group (NASDAQ:XXII) Stock Rating Lowered by StockNews.com

22nd Century Group (NASDAQ:XXII) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Tuesday.

22nd Century Group Stock Down 9.1 %

Shares of NASDAQ:XXII opened at $5.31 on Tuesday. The stock has a market cap of $2.94 million, a price-to-earnings ratio of -0.24 and a beta of 1.50. The business’s 50 day moving average is $11.01 and its 200 day moving average is $46.16. 22nd Century Group has a 12-month low of $3.90 and a 12-month high of $581.85. The company has a quick ratio of 0.93, a current ratio of 1.09 and a debt-to-equity ratio of 1.59.

22nd Century Group (NASDAQ:XXII) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($72.90) earnings per share (EPS) for the quarter. The firm had revenue of $5.95 million for the quarter. 22nd Century Group had a negative return on equity of 380.39% and a negative net margin of 144.09%.

Institutional Trading of 22nd Century Group

A hedge fund recently bought a new stake in 22nd Century Group stock. Anson Funds Management LP bought a new stake in 22nd Century Group, Inc. (NASDAQ:XXII) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 3,140,452 shares of the biotechnology company’s stock, valued at approximately $691,000. Anson Funds Management LP owned about 6.77% of 22nd Century Group as of its most recent SEC filing. 18.06% of the stock is owned by institutional investors and hedge funds.

About 22nd Century Group

22nd Century Group, Inc, a tobacco products company, engages in the sale and distribution of its own proprietary new reduced nicotine tobacco products. The company offers reduced nicotine content tobacco plants and very low nicotine combustible cigarette products. It also provides contract manufacturing services for conventional combustible tobacco products for third-party brands.